41 results about "Gamithromycin" patented technology

The invention discloses a gamithromycin injection and a preparation method thereof. The gamithromycin injection is prepared from the components including gamithromycin, a cosolvent, an antioxidant and water for injection, and is characterized by comprising 5-35 g of gamithromycin, 1-15 ml of the cosolvent, 0.1-0.5 g of the antioxidant and the balance of water for injection in every 100 ml injection. The preparation method comprises the steps as follows: dissolving the cosolvent in the water for injection, continuously adding gamithromycin and stirring to enable the gamithromycin to be dissolved, then adding the antioxidant to adjust pH to be 4.0-6.0, filtering and sterilizing, so that the gamithromycin injection is obtained. The gamithromycin injection is stable in properties, fast in absorption, remarkable in effect and simple in the preparation method, has less irritation to an injection part, effectively solves the problem that the gamithromycin is indissolvable in water, and meets the requirement of mass industrial production.

The invention provides a method for detecting the content of gamithromycin. The method comprises the steps: dissolving a gamithromycin sample to be detected by a flowing phase, and performing liquid phase chromatogram quantitative analysis by using a DAD (Dioxide Array Detector) detector adopting C8 and C18 chromatographic columns, wherein chromatographic conditions are as follows: the flowing phase is as follows: a weight ratio of acetonitrile to 0.025mol/ml dipotassium phosphate solution (PH8-8.5) is 70:30, a flow velocity is 1.00-2.00ml/min, and a detection wavelength is 210-230nm. The method is accurate and simple, and is good in reproducibility and high in sensitivity.

The invention discloses a gamithromycin composition lyophilized powder for injection. The gamithromycin composition lyophilized powder contains gamithromycin serving as an active ingredient and pharmaceutical excipients, the pharmaceutical excipients are at least one of citric acid, L-malic acid, tartaric acid and succinic acid, the weight ratio of the active ingredient and the pharmaceutical excipients is 1:0.27-0.65, and the pH value of a solution is adjusted to be 5.5-6.0 by using sodium hydroxide before lyophilizing. The invention further provides a preparation method of the gamithromycin composition lyophilized powder for injection. By the method, sterile gamithromycin composition lyophilized powder can be prepared; during clinic use, the gamithromycin composition lyophilized powder is dissolved in sterile normal saline, the solution is small in viscosity, easy for suction and easy for injection, and the gamithromycin composition lyophilized powder is simple and convenient in clinic use and small in irritancy to animals. Consequently, stability, safety and convenience in use of gamithromycin for injection are improved.

The invention discloses a gamithromycin injection and a preparation method thereof. The gamithromycin injection is composed of gamithromycin, vitamin C and water for injection. Every 100 ml of the gamithromycin injection comprises 5-35 g of gamithromycin, 1-10 g of vitamin C and the balance water for injection. In the gamithromycin injection, the vitamin C is used to increase a dissolving speed and a solubility of the gamithromycin raw medicine, has a very good solubilizing effect, also has an antioxidant effect, and can improve stability of the product. The gamithromycin injection is a weaklyacidic water-phase injection, can be matched with most of medicines for use, greatly increases long-term storage stability of gamithromycin, has small irritation to an injection part, quick absorption, a remarkable effect, high safety and simple prescription, is convenient for controlling quality of raw materials and auxiliary materials, saves cost, and is suitable for industrial production.

The invention provides a content detection method of gamithromycin. According to the technical scheme, the content of gamithromycin is detected by virtue of a HPLC method; an evaporative light-scattering detector is utilized, is high in sensitivity and is not sensitive to temperature variation, and a base line is relatively stable; the response of the evaporative light-scattering detector does not depend on the optical property of a sample, is not influenced by functional groups, is not interfered by a mobile phase and is in direct proportion to the quality of the sample, and specific chemical structures of detected main components are not required; the gamithromycin is relatively low in absorption wavelength and is absorbed at a tail end of an ultraviolet ray; therefore, compared with an ultraviolet detector, the evaporative light-scattering detector has great superiority in the detection of gamithromycin. Besides, selected chromatographic columns and chromatographic conditions are designed tightly around the characteristic of the evaporative light-scattering detector, a relatively good separation effect is integrally realized; after the method is verified by virtue of methods such as an accuracy experiment, a linear relation experiment and a sampling recycling experiment, results show that the accuracy is high, the detection range is wide, and the sensitivity is relatively good.

The invention relates to a gamithromycin emulsion. Each 100g of the gamithromycin emulsion comprises the following components by weight of 0.01 to 5.0 g of gamithromycin, 0.1 to 16.0 g of lysimachia christinae hance oil, 0.1 to 5.0 g of ethyl linoleate, 8.0 to 30.0 g of sucrose fatty acid ester, 10.0 to 20.0 g of polyoxyethylene ether (60) hydrogenated castor oil, 5.0 to 10.0 g of 1, 2-propylene glycol and the balance of deionized water. Meanwhile, the invention further discloses a preparation method, the process operability is high, and production conversion is facilitated. The emulsion disclosed by the invention is in an oil-water mutual wrapping type, the prepared product can be infinitely diluted with water and can also be infinitely diluted with oil, after being diluted with water, the emulsion can meet the drinking water administration requirement and is convenient to use, and after being diluted with oil, the emulsion can be prepared into a slow-release emulsion, so that a long-acting antibacterial effect is achieved, and the administration frequency is reduced. The emulsion disclosed by the invention can be used for preventing and treating ileitis diseases caused by pig Lawsonia intracellularis infection, has an effect obviously better than that of the prior art, and has a wide market application prospect.

The invention relates to a preparation method of a Gamithromycin intermediate. The method includes: taking 9-deoxy-6-deoxy-6, 9-imino ether-(8a-aza-8a)-erythromycin A as the raw material, dissolving it in an organic solvent, adjusting the pH to 3-6 with acid, adopting potassium borohydride or sodium borohydride as a reducing agent to conduct reduction reaction; and then adding organic sugar acid to undergo hydrolysis reaction to obtain 9-deoxy-8a-aza-8a-homoerythromycin A. As the organic sugar acid contains hydroxyl and is conducive to hydrolysis of a Gamithromycin borate intermediate, the acid degradation product is reduced, and hydrolysis of 9-deoxy-6-deoxy-6, 9-imino ether-(8a-aza-8a)-erythromycin A can be effectively reduced, the yield of the target product is enhanced, and the preparation cost of the Gamithromycin intermediate 9-deoxy-8a-aza-8a-homoerythromycin A can be significantly reduced. Thus, the preparation method is convenient for industrial production.

The invention discloses gamithromycin injection and a preparation method thereof, and belongs to the technical field of veterinary pharmaceutical preparations. The gamithromycin injection comprises the following components: gamithromycin, an inclusion agent, an antioxidant, ethanol and water for injection, wherein the inclusion agent is hydroxypropyl-beta-cyclodextrin or sulfobutyl ether-beta-cyclodextrin. According to the injection prepared by carrying out an inclusion reaction on the gamithromycin and the inclusion agent to form an inclusion compound, the defect that the gamithromycin is insoluble in water is overcome, the defects that the gamithromycin injection is easy to crystallize, poor in stability, high in viscosity and serious in animal stress reaction are overcome, and product storage and clinical application are facilitated.

The invention discloses a preparation method of gamithromycin or a 13-descladinosylation compound serving as a precursor of gamithromycin, belonging to the field of chemical synthesis. The method comprises the steps of adding a reaction substrate and a solvent into a high-pressure kettle, wherein the reaction substrate is gamithromycin or the precursor thereof, and the solvent is low-grade amide, low-grade ketone or low-grade alcohol; adding acid, and controlling the pH value of a reaction system at 0.5-5; introducing nitrogen gas to the high-pressure kettle, and keeping the pressure at 0.1-0.8Mpa; and controlling the reaction temperature at 0-35 DEG C and stirring for 1-12 hours. The preparation method is simple in process and high in selectivity, and the yield of gamithromycin or the 13-descladinosylation compound serving as the precursor of gamithromycin is high. Gamithromycin or the precursor thereof contains hydroxyls, ester groups and a plurality of ether bonds; and the reaction substrate of gamithromycin and the precursor thereof in the method disclosed by the invention selectively breaks the ether bonds at the juncture of cladinose and a matrix under an acid condition, but the hydroxyls and the ester groups are unchanged under the reaction condition, so that the selectivity is high.

The invention discloses a gamithromycin sustained-release preparation and a preparation method thereof. The gamithromycin sustained-release preparation comprises the following components in parts by weight: 5-50 parts of gamithromycin, 10-40 parts of a sustained-release framework material and 10-85 parts of auxiliary materials, the sustained-release framework material is prepared from xanthan gum, sodium carboxymethyl cellulose and carrageenan according to the mass ratio of 1: 1: 1, and the auxiliary material is prepared from soluble starch and Jiyi powder according to the mass ratio of 2: 1. The gamithromycin sustained-release preparation prepared by the invention is convenient to take, good in compliance, good in sustained-release effect, good in stability, high in drug loading capacity and high in safety; and the preparation process is convenient and rapid, and is beneficial to industrial large-scale production.

The invention relates to the technical field of chemical synthesis, in particular to a method for preparing gamithromycin. According to the preparation method, 9-deoxy-8a-aza-high erythromycin A and n-propanal are taken as raw materials, hydrogen is taken as a reducing agent, reaction is performed under the catalytic action of Pd/NiO, and gamithromycin is obtained. According to the preparation method, the reaction process is mild, no special hydrogenation device is required, and the production is amplified easily; a catalyst can be recycled many times, the production cost is reduced, and the method is more economical and environmentally friendly and conforms to large-scale industrial production requirements.

The invention provides a preparation method of a gamithromycin composite solution, and relates to the technical field of veterinary drug antibiotics. The preparation method of the gamithromycin-based composite solution comprises a premix, gamithromycin freeze-dried powder, a cosolvent, a solubilizer, a substrate solvent, a pH value neutralizer and a pH value buffer, and comprises the following steps: precisely weighing 20 parts of the premix, and pouring into a water bath mixing tank for later use; and taking 5-10 parts of the gamithromycin freeze-dried powder, adding the gamithromycin freeze-dried powder into the mixing tank in which the premix is added, then adding 0.8-1.2 parts of the cosolvent, heating in a water bath at the temperature of 60-80 DEG C for 20-30 minutes, and stirring and mixing by using stirring equipment. According to invention, the gamithromycin can be dissolved in the organic solvent in advance by using the premix, and then is mixed with the substrate solvent through the solubilizer, so that the irritation of the composite solution is successfully reduced under the condition of ensuring the solubility of the gamithromycin, and the practicability of the composite solution is improved.

The present invention relates to a gamithromycin composition, which comprises 1-40% of a gamithromycin soluble salt, and other solubilizing components. According to the present invention, the gamithromycin composition can be administered orally so as to reduce the labor intensity of drug application, can reduce antibiotic consumption, and further has high treatment effect, wherein the cure rate ofthe gamithromycin composition is 5-15% higher than the cure rate of the similar products.

The invention provides a composition. The composition is composed of gamithromycin, polyvinylpyrrolidone and a pharmaceutically acceptable carrier. The composition has the advantages of being long in plasma concentration retention time and low in composition cost.

The invention provides a method for detecting the gamithromycin content. The method is high performance liquid chromatography, a C18 chromatographic column is used to enforce separation, a UV detectoris used to carry out quantitative analysis, and chromatographic conditions are as follows: the mobile phase comprises a dipotassium hydrogen phosphate solution with the pH value being 7.8-8.2 and theconcentration being 0.01 mol/L and 60-80% (v/v) of acetonitrile; the flow velocity is 0.8-1.2 mL/min; the column temperature is 35-45 DEG C; and the detection wavelength is 210 nm. The composition, the kind, the concentration and the ratio of the mobile phase are selected in the method to reach a high sensitivity and a high separation degree by using the UV detector, so the problems of high priceand use convenience, brought by selection of an evaporative light-scattering detector for improving the sensitivity and the separation effect in the prior art, are solved. The method has the advantages of simplicity, easiness in operation, accurate and reliable result, high sensitivity, good reappearance, high separation degree, low cost, cheap and easily available device and reagents, and convenience in promotion and application.

The invention discloses a gamithromycin microemulsion for injection and a preparation method thereof. The preparation method comprises the following steps: adding an oil phase solvent and gamithromycin or gamithromycin salt into reaction equipment with a preset temperature, performing stirring until the mixture is dissolved, and then performing cooling to room temperature; adding an emulsifier, a co-emulsifier and water for injection into the reaction equipment until a preparation is homogeneous and stable to obtain an intermediate; and carrying out sterilization treatment on the intermediate to obtain a finished product. The gamithromycin microemulsion for injection comprises the following components in percentage by mass: 1%-30% of gamithromycin or salts thereof, 10%-50% of oil-phase solvent, 1.5%-10% of emulsifier, 1.5%-10% of co-emulsifier and 1%-85% of water for injection. The gamithromycin microemulsion for injection provided by the invention is simple in preparation process and relatively low in cost, the prepared finished product is high in stability, and the injection irritation is within a safe range.

The invention provides a method for determining gamithromycin related substances, and belongs to the technical field of column chromatography test or analysis materials. The gamithromycin related substances refer to impurities introduced in a gamithromycin synthesis process or generated by degradation. The method is applied to determination of gamithromycin related substances, and has the advantages of stable chromatographic condition system, good linearity, high precision, high chromatographic condition sensitivity, good specificity, stable determination solution within 35 h, and the like.

The invention relates to a gamithromycin crystal form I and a preparation method thereof. According to the gamithromycin crystal form I, Cu-Ka radiation is used, X-ray powder diffraction shown by an angle 2(theta) is carried out, and the gamithromycin crystal form I has characteristic absorption peaks at 6.8165 degrees +/- 0.3 degree, 9.5249 degrees +/- 0.3 degree, 10.1349 degrees +/- 0.3 degree, 11.4490 degrees +/- 0.3 degree, 12.9373 degrees +/- 0.3 degree, 14.9831 degrees +/- 0.3 degree, 19.2302 degrees +/- 0.3 degree and 20.5137 +/- 0.3 degree. The gamithromycin crystal form I provided by the invention is easy to prepare, and related test data shows that the gamithromycin crystal form I is high purity, low in impurity content and good in stability.